Watson Pharmaceuticals has completed the acquisition of Belgium-based Uteron Pharma SA for $150 million in cash, and as much as $155 million in potential future milestone payments. The acquisition expands Watson’s pipeline of women’s health products, including two potential commercial opportunities in contraception and infertility, and one oral contraceptive projected to launch globally in 2018. The acquisition also includes several products in earlier stages of development.   &#8220...